Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Enzo Biochem's Capital Expenditure for the
three
months ended in Jan. 2024 was $-0.03 Mil. Its Revenue for the
three
months ended in Jan. 2024 was $8.55 Mil.
Hence, Enzo Biochem's Capex-to-Revenue for the
three
months ended in Jan. 2024 was 0.00.
Enzo Biochem Capex-to-Revenue Historical Data
The historical data trend for Enzo Biochem's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Enzo Biochem's Capex-to-Revenue
For the Diagnostics & Research subindustry, Enzo Biochem's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzo Biochem's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Enzo Biochem's Capex-to-Revenue falls into.
Enzo Biochem Capex-to-Revenue Calculation
Enzo Biochem's Capex-to-Revenue for the fiscal year that ended in Jul. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Enzo Biochem Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Enzo Biochem's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENZ has been successfully added to your 